Current agents are monoclonal antibodies targeting either cytotoxic T-lymphocyte antigen 4 (CTLA-4) programmed cell death 1 (PD-1) or its ligand PD-L1 to potentiate anti-tumor immune responses. The gene discussed is PDCD1; the disease is neoplasm.